The global Opioid-Induced Constipation market size was valued at USD 2604.3 million in 2022 and is forecast to a readjusted size of USD 3520.9 million by 2029 with a CAGR of 4.4% during review period.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%. North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent. In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
This report is a detailed and comprehensive analysis for global Opioid-Induced Constipation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Opioid-Induced Constipation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Opioid-Induced Constipation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Opioid-Induced Constipation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Opioid-Induced Constipation market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Hospital
Pharmacy
Other
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Opioid-Induced Constipation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Opioid-Induced Constipation, with price, sales, revenue and global market share of Opioid-Induced Constipation from 2018 to 2023.
Chapter 3, the Opioid-Induced Constipation competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Opioid-Induced Constipation breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Opioid-Induced Constipation.
Chapter 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Opioid-Induced Constipation
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Opioid-Induced Constipation Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Methylnaltrexone Bromide
1.3.3 Lubiprostone
1.3.4 Naloxegol
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Opioid-Induced Constipation Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Other
1.5 Global Opioid-Induced Constipation Market Size & Forecast
1.5.1 Global Opioid-Induced Constipation Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Opioid-Induced Constipation Sales Quantity (2018-2029)
1.5.3 Global Opioid-Induced Constipation Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Takeda Pharmaceuticals
2.1.1 Takeda Pharmaceuticals Details
2.1.2 Takeda Pharmaceuticals Major Business
2.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
2.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Pharmaceuticals Recent Developments/Updates
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Opioid-Induced Constipation Product and Services
2.2.4 Bayer Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bayer Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Opioid-Induced Constipation Product and Services
2.3.4 Sanofi Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sanofi Recent Developments/Updates
2.4 Mallinckrodt
2.4.1 Mallinckrodt Details
2.4.2 Mallinckrodt Major Business
2.4.3 Mallinckrodt Opioid-Induced Constipation Product and Services
2.4.4 Mallinckrodt Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Mallinckrodt Recent Developments/Updates
2.5 Salix (Bausch Health)
2.5.1 Salix (Bausch Health) Details
2.5.2 Salix (Bausch Health) Major Business
2.5.3 Salix (Bausch Health) Opioid-Induced Constipation Product and Services
2.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Salix (Bausch Health) Recent Developments/Updates
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Opioid-Induced Constipation Product and Services
2.6.4 AstraZeneca Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AstraZeneca Recent Developments/Updates
2.7 Progenics Pharmaceuticals
2.7.1 Progenics Pharmaceuticals Details
2.7.2 Progenics Pharmaceuticals Major Business
2.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
2.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Progenics Pharmaceuticals Recent Developments/Updates
2.8 Purdue Pharm
2.8.1 Purdue Pharm Details
2.8.2 Purdue Pharm Major Business
2.8.3 Purdue Pharm Opioid-Induced Constipation Product and Services
2.8.4 Purdue Pharm Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Purdue Pharm Recent Developments/Updates
2.9 Nektar Therapeutics
2.9.1 Nektar Therapeutics Details
2.9.2 Nektar Therapeutics Major Business
2.9.3 Nektar Therapeutics Opioid-Induced Constipation Product and Services
2.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Nektar Therapeutics Recent Developments/Updates
2.10 Daiichi Sankyo
2.10.1 Daiichi Sankyo Details
2.10.2 Daiichi Sankyo Major Business
2.10.3 Daiichi Sankyo Opioid-Induced Constipation Product and Services
2.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Daiichi Sankyo Recent Developments/Updates
2.11 Prestige
2.11.1 Prestige Details
2.11.2 Prestige Major Business
2.11.3 Prestige Opioid-Induced Constipation Product and Services
2.11.4 Prestige Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Prestige Recent Developments/Updates
2.12 GSK
2.12.1 GSK Details
2.12.2 GSK Major Business
2.12.3 GSK Opioid-Induced Constipation Product and Services
2.12.4 GSK Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 GSK Recent Developments/Updates
2.13 Shionogi
2.13.1 Shionogi Details
2.13.2 Shionogi Major Business
2.13.3 Shionogi Opioid-Induced Constipation Product and Services
2.13.4 Shionogi Opioid-Induced Constipation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Shionogi Recent Developments/Updates
3 Competitive Environment: Opioid-Induced Constipation by Manufacturer
3.1 Global Opioid-Induced Constipation Sales Quantity by Manufacturer (2018-2023)
3.2 Global Opioid-Induced Constipation Revenue by Manufacturer (2018-2023)
3.3 Global Opioid-Induced Constipation Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Opioid-Induced Constipation by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Opioid-Induced Constipation Manufacturer Market Share in 2022
3.4.2 Top 6 Opioid-Induced Constipation Manufacturer Market Share in 2022
3.5 Opioid-Induced Constipation Market: Overall Company Footprint Analysis
3.5.1 Opioid-Induced Constipation Market: Region Footprint
3.5.2 Opioid-Induced Constipation Market: Company Product Type Footprint
3.5.3 Opioid-Induced Constipation Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Opioid-Induced Constipation Market Size by Region
4.1.1 Global Opioid-Induced Constipation Sales Quantity by Region (2018-2029)
4.1.2 Global Opioid-Induced Constipation Consumption Value by Region (2018-2029)
4.1.3 Global Opioid-Induced Constipation Average Price by Region (2018-2029)
4.2 North America Opioid-Induced Constipation Consumption Value (2018-2029)
4.3 Europe Opioid-Induced Constipation Consumption Value (2018-2029)
4.4 Asia-Pacific Opioid-Induced Constipation Consumption Value (2018-2029)
4.5 South America Opioid-Induced Constipation Consumption Value (2018-2029)
4.6 Middle East and Africa Opioid-Induced Constipation Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
5.2 Global Opioid-Induced Constipation Consumption Value by Type (2018-2029)
5.3 Global Opioid-Induced Constipation Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
6.2 Global Opioid-Induced Constipation Consumption Value by Application (2018-2029)
6.3 Global Opioid-Induced Constipation Average Price by Application (2018-2029)
7 North America
7.1 North America Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
7.2 North America Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
7.3 North America Opioid-Induced Constipation Market Size by Country
7.3.1 North America Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
7.3.2 North America Opioid-Induced Constipation Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
8.2 Europe Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
8.3 Europe Opioid-Induced Constipation Market Size by Country
8.3.1 Europe Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
8.3.2 Europe Opioid-Induced Constipation Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Opioid-Induced Constipation Market Size by Region
9.3.1 Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
10.2 South America Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
10.3 South America Opioid-Induced Constipation Market Size by Country
10.3.1 South America Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
10.3.2 South America Opioid-Induced Constipation Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Opioid-Induced Constipation Market Size by Country
11.3.1 Middle East & Africa Opioid-Induced Constipation Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Opioid-Induced Constipation Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Opioid-Induced Constipation Market Drivers
12.2 Opioid-Induced Constipation Market Restraints
12.3 Opioid-Induced Constipation Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Opioid-Induced Constipation and Key Manufacturers
13.2 Manufacturing Costs Percentage of Opioid-Induced Constipation
13.3 Opioid-Induced Constipation Production Process
13.4 Opioid-Induced Constipation Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Opioid-Induced Constipation Typical Distributors
14.3 Opioid-Induced Constipation Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Opioid-Induced Constipation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Opioid-Induced Constipation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceuticals Major Business
Table 5. Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 6. Takeda Pharmaceuticals Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Takeda Pharmaceuticals Recent Developments/Updates
Table 8. Bayer Basic Information, Manufacturing Base and Competitors
Table 9. Bayer Major Business
Table 10. Bayer Opioid-Induced Constipation Product and Services
Table 11. Bayer Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Bayer Recent Developments/Updates
Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
Table 14. Sanofi Major Business
Table 15. Sanofi Opioid-Induced Constipation Product and Services
Table 16. Sanofi Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Sanofi Recent Developments/Updates
Table 18. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 19. Mallinckrodt Major Business
Table 20. Mallinckrodt Opioid-Induced Constipation Product and Services
Table 21. Mallinckrodt Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Mallinckrodt Recent Developments/Updates
Table 23. Salix (Bausch Health) Basic Information, Manufacturing Base and Competitors
Table 24. Salix (Bausch Health) Major Business
Table 25. Salix (Bausch Health) Opioid-Induced Constipation Product and Services
Table 26. Salix (Bausch Health) Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Salix (Bausch Health) Recent Developments/Updates
Table 28. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 29. AstraZeneca Major Business
Table 30. AstraZeneca Opioid-Induced Constipation Product and Services
Table 31. AstraZeneca Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. AstraZeneca Recent Developments/Updates
Table 33. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Progenics Pharmaceuticals Major Business
Table 35. Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 36. Progenics Pharmaceuticals Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Progenics Pharmaceuticals Recent Developments/Updates
Table 38. Purdue Pharm Basic Information, Manufacturing Base and Competitors
Table 39. Purdue Pharm Major Business
Table 40. Purdue Pharm Opioid-Induced Constipation Product and Services
Table 41. Purdue Pharm Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Purdue Pharm Recent Developments/Updates
Table 43. Nektar Therapeutics Basic Information, Manufacturing Base and Competitors
Table 44. Nektar Therapeutics Major Business
Table 45. Nektar Therapeutics Opioid-Induced Constipation Product and Services
Table 46. Nektar Therapeutics Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Nektar Therapeutics Recent Developments/Updates
Table 48. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 49. Daiichi Sankyo Major Business
Table 50. Daiichi Sankyo Opioid-Induced Constipation Product and Services
Table 51. Daiichi Sankyo Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Daiichi Sankyo Recent Developments/Updates
Table 53. Prestige Basic Information, Manufacturing Base and Competitors
Table 54. Prestige Major Business
Table 55. Prestige Opioid-Induced Constipation Product and Services
Table 56. Prestige Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Prestige Recent Developments/Updates
Table 58. GSK Basic Information, Manufacturing Base and Competitors
Table 59. GSK Major Business
Table 60. GSK Opioid-Induced Constipation Product and Services
Table 61. GSK Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. GSK Recent Developments/Updates
Table 63. Shionogi Basic Information, Manufacturing Base and Competitors
Table 64. Shionogi Major Business
Table 65. Shionogi Opioid-Induced Constipation Product and Services
Table 66. Shionogi Opioid-Induced Constipation Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Shionogi Recent Developments/Updates
Table 68. Global Opioid-Induced Constipation Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 69. Global Opioid-Induced Constipation Revenue by Manufacturer (2018-2023) & (USD Million)
Table 70. Global Opioid-Induced Constipation Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 71. Market Position of Manufacturers in Opioid-Induced Constipation, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 72. Head Office and Opioid-Induced Constipation Production Site of Key Manufacturer
Table 73. Opioid-Induced Constipation Market: Company Product Type Footprint
Table 74. Opioid-Induced Constipation Market: Company Product Application Footprint
Table 75. Opioid-Induced Constipation New Market Entrants and Barriers to Market Entry
Table 76. Opioid-Induced Constipation Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
Table 78. Global Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
Table 79. Global Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
Table 80. Global Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
Table 81. Global Opioid-Induced Constipation Average Price by Region (2018-2023) & (USD/Unit)
Table 82. Global Opioid-Induced Constipation Average Price by Region (2024-2029) & (USD/Unit)
Table 83. Global Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Global Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Global Opioid-Induced Constipation Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Global Opioid-Induced Constipation Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Global Opioid-Induced Constipation Average Price by Type (2018-2023) & (USD/Unit)
Table 88. Global Opioid-Induced Constipation Average Price by Type (2024-2029) & (USD/Unit)
Table 89. Global Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 90. Global Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 91. Global Opioid-Induced Constipation Consumption Value by Application (2018-2023) & (USD Million)
Table 92. Global Opioid-Induced Constipation Consumption Value by Application (2024-2029) & (USD Million)
Table 93. Global Opioid-Induced Constipation Average Price by Application (2018-2023) & (USD/Unit)
Table 94. Global Opioid-Induced Constipation Average Price by Application (2024-2029) & (USD/Unit)
Table 95. North America Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 96. North America Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 97. North America Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 98. North America Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 99. North America Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
Table 100. North America Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
Table 101. North America Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
Table 102. North America Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Europe Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 104. Europe Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 105. Europe Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 106. Europe Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 107. Europe Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
Table 108. Europe Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
Table 109. Europe Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 112. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 113. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 114. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 115. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
Table 116. Asia-Pacific Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
Table 117. Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
Table 118. Asia-Pacific Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
Table 119. South America Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 120. South America Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 121. South America Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 122. South America Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 123. South America Opioid-Induced Constipation Sales Quantity by Country (2018-2023) & (K Units)
Table 124. South America Opioid-Induced Constipation Sales Quantity by Country (2024-2029) & (K Units)
Table 125. South America Opioid-Induced Constipation Consumption Value by Country (2018-2023) & (USD Million)
Table 126. South America Opioid-Induced Constipation Consumption Value by Country (2024-2029) & (USD Million)
Table 127. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2018-2023) & (K Units)
Table 128. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Type (2024-2029) & (K Units)
Table 129. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2018-2023) & (K Units)
Table 130. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Application (2024-2029) & (K Units)
Table 131. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Region (2018-2023) & (K Units)
Table 132. Middle East & Africa Opioid-Induced Constipation Sales Quantity by Region (2024-2029) & (K Units)
Table 133. Middle East & Africa Opioid-Induced Constipation Consumption Value by Region (2018-2023) & (USD Million)
Table 134. Middle East & Africa Opioid-Induced Constipation Consumption Value by Region (2024-2029) & (USD Million)
Table 135. Opioid-Induced Constipation Raw Material
Table 136. Key Manufacturers of Opioid-Induced Constipation Raw Materials
Table 137. Opioid-Induced Constipation Typical Distributors
Table 138. Opioid-Induced Constipation Typical Customers
List of Figures
Figure 1. Opioid-Induced Constipation Picture
Figure 2. Global Opioid-Induced Constipation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Opioid-Induced Constipation Consumption Value Market Share by Type in 2022
Figure 4. Methylnaltrexone Bromide Examples
Figure 5. Lubiprostone Examples
Figure 6. Naloxegol Examples
Figure 7. Others Examples
Figure 8. Global Opioid-Induced Constipation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Opioid-Induced Constipation Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Pharmacy Examples
Figure 12. Other Examples
Figure 13. Global Opioid-Induced Constipation Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Opioid-Induced Constipation Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Opioid-Induced Constipation Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Opioid-Induced Constipation Average Price (2018-2029) & (USD/Unit)
Figure 17. Global Opioid-Induced Constipation Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Opioid-Induced Constipation Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Opioid-Induced Constipation by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Opioid-Induced Constipation Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Opioid-Induced Constipation Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Opioid-Induced Constipation Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Opioid-Induced Constipation Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Opioid-Induced Constipation Average Price by Type (2018-2029) & (USD/Unit)
Figure 32. Global Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Opioid-Induced Constipation Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Opioid-Induced Constipation Average Price by Application (2018-2029) & (USD/Unit)
Figure 35. North America Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
Figure 55. China Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Opioid-Induced Constipation Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Opioid-Induced Constipation Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Opioid-Induced Constipation Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Opioid-Induced Constipation Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Opioid-Induced Constipation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Opioid-Induced Constipation Market Drivers
Figure 76. Opioid-Induced Constipation Market Restraints
Figure 77. Opioid-Induced Constipation Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2022
Figure 80. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 81. Opioid-Induced Constipation Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
